Ovarian Cancer Clinical Trials in Rochester, Minnesota

14 studies are recruiting for ovarian cancer in Rochester, Minnesota right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

   This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Rochester, Rochester, Minnesota

   Locations

   20 in total

   Run by

   Terremoto Biosciences Inc.

   See if you can join NCT07109726 on ClinicalTrials.gov

2. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

   Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Desi…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Mayo Clinic Rochester, Rochester, Minnesota

   Locations

   16 in total

   Run by

   A2 Biotherapeutics Inc.

   See if you can join NCT04981119 on ClinicalTrials.gov

3. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

   This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic (Minnesota), Rochester, Minnesota

   Locations

   82 in total

   Run by

   Artios Pharma Ltd

   See if you can join NCT04657068 on ClinicalTrials.gov

4. Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

   The proposed study design is a single arm Phase II trial to document the feasibility of carboplatin-mirvetuximab - in patients with advanced-stage EOC. Patients with biopsy confirmed, newly diagnosed, advanced-stage serous EOC deemed appropriate for NACT will have their tumors evaluated for FRα rec…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Mayo Clinic, Rochester, Minnesota

   Locations

   9 in total

   Run by

   University of Alabama at Birmingham

   See if you can join NCT04606914 on ClinicalTrials.gov

5. Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

   This Phase 3 study is designed to investigate the safety, diagnostic performance, and clinical usefulness of Gleolan for the real-time detection and visualization of epithelial ovarian cancer tumors during debulking surgery. The study is planned to run for about 18 months with individual study part…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Mayo Clinic Methodist Campus, Rochester, Minnesota

   Locations

   11 in total

   Run by

   NX Development Corp

   See if you can join NCT05804370 on ClinicalTrials.gov

6. Lead-212 PSV359 Therapy for Patients With Solid Tumors

   Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

   Stage

   Phase 1

   Ages

   18 to 90

   Site

   Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota

   Locations

   11 in total

   Run by

   Perspective Therapeutics

   See if you can join NCT06710756 on ClinicalTrials.gov

7. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

   A Study of Emi-Le in Participants with Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic - Rochester, Rochester, Minnesota

   Locations

   26 in total

   Run by

   Day One Biopharmaceuticals, Inc.

   See if you can join NCT05377996 on ClinicalTrials.gov

8. Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

   This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence

   Stage

   Not phased

   Ages

   18 and older

   Site

   Mayo Clinic, Rochester, Minnesota

   Locations

   9 in total

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT05287451 on ClinicalTrials.gov

9. A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

   The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesotheli…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic Rochester, Rochester, Minnesota

   Locations

   12 in total

   Run by

   A2 Biotherapeutics Inc.

   See if you can join NCT06051695 on ClinicalTrials.gov

10. Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

    The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. This prop…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Mayo Clinic, Rochester, Minnesota

    Locations

    24 in total

    Run by

    Mayo Clinic

    See if you can join NCT05051722 on ClinicalTrials.gov

11. TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

    The aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence.

    Stage

    Not phased

    Ages

    25 to 50

    Site

    Mayo Clinic, Rochester, Minnesota

    Locations

    66 in total

    Run by

    University Medical Center Nijmegen

    See if you can join NCT04294927 on ClinicalTrials.gov

12. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

    This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic, Rochester, Minnesota

    Locations

    14 in total

    Run by

    858 Therapeutics, Inc.

    See if you can join NCT06395519 on ClinicalTrials.gov

13. First in Human Study of TORL-1-23 in Participants With Advanced Cancer

    This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic in Rochester, Rochester, Minnesota

    Locations

    14 in total

    Run by

    TORL Biotherapeutics, LLC

    See if you can join NCT05103683 on ClinicalTrials.gov

14. cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

    This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gast…

    Stage

    Not phased

    Ages

    40 and older

    Site

    Mayo Clinic, Rochester, Minnesota

    Locations

    17 in total

    Run by

    Adela, Inc

    See if you can join NCT05366881 on ClinicalTrials.gov